Safety and Effectiveness of Giving CPI-1189 to HIV-Infected Patients With AIDS Dementia

Status unconfirmed · Phase 2

Conditions studied: HIV Infections

In brief

The purpose of this study is to see if it is safe and effective to give CPI-1189 to patients with AIDS dementia. Advanced HIV infection can cause AIDS dementia (brain damage due to HIV leading to loss of memory and muscle control). CPI-1189 may be able to postpone AIDS dementia or slow it down.

Key facts

Study ID

NCT00002414

Run by

Centaur Pharmaceuticals

People needed

60

Last updated by the study team

2005-06-24

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• You may be eligible for this study if you:
• Are HIV-positive.
• Are at least 18 years old.
• Have symptoms of AIDS dementia including forgetfulness, loss of concentration, slow mental processing, or a loss of muscle control.
• Have been on stable anti-HIV drug therapy for the past 6 weeks (if you are taking anti-HIV drugs).

You may not qualify if…

• You will not be eligible for this study if you:
• Have certain serious medical conditions, such as a mental disorder or an opportunistic (AIDS-related) infection.

Where it is running

• Alzheimers Disease Research Ctr 0948 / UCSD — San Diego, California, United States
• Northwestern Univ / Dept of Neurology — Chicago, Illinois, United States
• Johns Hopkins Hosp / Dept of Neurology / Meyer 6109 — Baltimore, Maryland, United States
• Washington Univ Sch of Med / Dept of Neurology — St Louis, Missouri, United States
• Columbia Univ / Sergievsky Ctr Physicians and Surgeons — New York, New York, United States
• Univ of Rochester / Strong Memorial Hosp — Rochester, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.